On July 24, 2025, in Zhengzhou, China, based on the local avian influenza epidemic situation in Vietnam, WixBio tailored an avian influenza H5 (N6+N8)+H9N2+Newcastle Disease (ND, G-7 strain) multivalent inactivated vaccine for the Vietnamese market. This vaccine, due to its excellent antibody levels and clinical protection rate after primary and secondary immunizations, has once again received bulk orders from Vietnamese customers, earning high praise.
This customized vaccine is precisely matched to the currently circulating avian influenza virus strains in Vietnam, covering the H5 subtype (N6 and N8 strains), H9N2 subtype, and Newcastle Disease G-7 strain, with good cross-protection capability and immunogenicity. Customer feedback indicates that after vaccination, the antibody titers in poultry flocks rise rapidly, providing significant immune protection that effectively controls the risk of avian influenza transmission and significantly reduces mortality and economic losses.
WixBio consistently adheres to a customer-centric and market-demand-oriented research and service philosophy, continuously optimizing vaccine strain matching technology to enhance product applicability and effectiveness under different regional and epidemic trends. This high recognition from Vietnamese customers once again proves the company’s professional strength and market responsiveness in the animal vaccine field.
To ensure vaccine quality and transportation safety, WixBio adopts a comprehensive cold-chain transportation solution, ensuring the vaccine reaches customers in optimal condition and guarantees unaffected immunization effects.
WixBio states that in the future, it will continue to strengthen cooperation with Vietnam and other overseas markets, conduct in-depth studies on local disease epidemic trends, and provide more precise and efficient vaccine solutions to support the healthy and sustainable development of global livestock farming.
